Cardinal Health stock follows 14 percent fiscal revenue growth

Published on 09/29/2026 at 06:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cardinal Health stock was last at USD 220.29 on September 28, 2026, while fiscal 2026 revenue reached USD 254.2 billion. Fiscal 2027 EPS guidance is 13 percent to 15 percent.

Fotorealistisches Pharma-Distributionslager mit Gabelstapler und Mitarbeitern in Dublin Ohio — Cardinal Health Inc. betreibt ein modernes Pharma-Distributionslager in Dublin, Ohio – ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health (ISIN US14149Y1082) was last at USD 220.29 on the NYSE on September 28, 2026 at 4:00 p.m. ET, while the healthcare distributor reported fiscal 2026 revenue of USD 254.2 billion, up 14 percent year over year. The latest investment case combines broad earnings growth with a fiscal 2027 adjusted EPS outlook above the company long-range target.

Fiscal revenue reaches USD 254.2 billion

StockTitan reported that fiscal 2026 revenue rose 14 percent to USD 254.2 billion for the year ended June 30, 2026. GAAP diluted EPS increased 12 percent to USD 7.23, while operating cash flow rose 116 percent to USD 5.2 billion.

The comparison matters because revenue growth was accompanied by faster cash generation and higher earnings. Non-GAAP diluted EPS reached USD 11.26, up 37 percent year over year, while adjusted non-GAAP diluted EPS increased 33 percent to USD 10.95 after excluding a USD 0.31 tariff-refund benefit.

Specialty growth lifts fiscal 2027 guide

At the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, Investing.com reported that Cardinal Health guided fiscal 2027 adjusted EPS growth of 13 percent to 15 percent. That exceeds the long-range target of 12 percent to 14 percent, creating a quantified improvement of 1 percentage point at the lower end and the same upper boundary.

The same conference account said specialty revenue passed USD 50 billion for the first time in fiscal 2026, while theranostics and PET growth reached close to 30 percent. Management also expects acquisitions to contribute 2 percent to 3 percent of profit growth in fiscal 2027, while demand assumptions are lower than the unusually strong first half of fiscal 2026.

Analyst target remains above USD 220.29

MarketBeat reported on September 14, 2026 that 16 analysts rated Cardinal Health Buy and three rated it Hold, producing a Moderate Buy consensus and an average 12-month price target of USD 266.56. The target stands USD 46.27 above the September 28 price, a 20.99 percent difference calculated from the NYSE reference price.

For investors, the central counterweight is the company operating model. Management described the business as running at a 1 percent margin and emphasized cost control, while fiscal 2027 guidance assumes strong demand but not the outsized demand seen in the first half of fiscal 2026.

Cardinal Health stock stays at USD 220.29

Cardinal Health stock was last at USD 220.29 on the NYSE on September 28, 2026 at 4:00 p.m. ET, up USD 0.07, or 0.03 percent, on the session. Its 52-week range was USD 150.78 to USD 258.30, and its market capitalization was USD 51.6 billion.